0
Abstract: Poster Presentations |

RESPONDER ANALYSES IN PATIENTS RECEIVING INFLIXIMAB FOR CHRONIC SARCOIDOSIS WITH PULMONARY INVOLVEMENT FREE TO VIEW

M. Drent, MD*; M. A. Judson, MD; U. Costabel, MD; R. M. duBois, MD; M. Kavuru, MD; K. H. Lo, MD; C. Andresen, MD; R. Schlenker-Herceg, MD; E. S. Barnathan, MD; R. P. Baughman, MD
Author and Funding Information

University Hospital of Maastricht, Maastricht, Netherlands


Chest


Chest. 2005;128(4_MeetingAbstracts):316S. doi:10.1378/chest.128.4_MeetingAbstracts.316S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  Response to drug therapy may not be uniform across a heterogeneous population. Responder analyses, which dichotomize the response at a specific level of interest, can be helpful in gauging the utility of an intervention. The objective of this study was to evaluate the response to infliximab therapy in a randomized trial of 138 patients with chronic pulmonary sarcoidosis using clinically meaningful dichotomous endpoints for pulmonary function, symptoms, and physical function.

METHODS:  Primary and major secondary endpoint data at 24 weeks from a placebo-controlled study of infliximab were explored. The analyses are presented as the number (%) of responders using varying definitions for improvements in forced vital capacity (FVC), St. George’s Respiratory Questionnaire (SGRQ) score, Borg’s CR10 dyspnea score post 6 minute walk (6MW), and 6 MW distance (6MWD).

RESULTS:  At week 24, there was a trend for more subjects having improved pulmonary function as measured by FVC with infliximab treatment using all definitions.All three groups responded similarly in SGRQ. For the combined infliximab group, there were more responders using Borg’s CR score post 6MW (p=0.028) or 6MWD (p=0.011). For 6MWD, the difference would translate into a number needed to treat (NNT) of 6.

CONCLUSION:  Responder analyses can be helpful in identifying clinically meaningful treatment effects, and can be useful to help gauge the NNT to achieve the level of benefit of interest.

CLINICAL IMPLICATIONS:  Infliximab appears to be associated with larger improvements in some endpoints in a subset of subjects, despite aggressive medical therapy. A larger trial of infliximab in such a population appears warranted.

DISCLOSURE:  M Drent, Grant monies (from industry related sources) Research grants; Consultant fee, speaker bureau, advisory committee, etc.; Employee.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543